ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1607

Risk Factors for Avascular Necrosis in SLE: A Multivariate Model

Romy Kallas1, Jessica Li 1 and Michelle Petri 1, 1Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Avascular necrosis, prednisone, risk and prednisolone, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors including African-American ethnicity, active disease, Raynaud’s, arthritis, cyclophosphamide use, and IgM anticardiolipin antibodies. In this analysis, we determined the predictors of AVN in a longitudinal lupus cohort in which Caucasian and African-American ethnicities were well represented.

Methods: We analyzed data from 1986 until April 2019. AVN was recorded using the Systemic Lupus Erythematosus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) Damage Index. Cox regression was used to identify variables that were associated with time to AVN. First, we assessed the univariate relationship between each variable and time to AVN. Those variables with significant association with time to AVN were then entered into the multivariable model; the ones that remained significant were retained in the final model. Variables that were highly colinear with highest prednisone were not included in the same model. Hazard ratios (HR) and 95% confidence intervals were reported.

Results: This analysis included 2477 patients who were 92.2% female, 39.1% African American, and 52.8% Caucasian. Non- Caucasian patients, male gender, obesity and history of vasculitis conferred a higher risk of AVN. Patients who received prednisone doses more than 60 mg had 10 times the risk of having an AVN, regardless of the duration of treatment, compared to patient who did not receive any prednisone. Patient who were on prednisone 40 mg daily had 6 times the risk of having AVN if the duration of treatment was more than 1 month compared to those who did not receive any prednisone (Table 1). The association between AVN and antiphospholipid antibodies (lupus anticoagulant) was only significant in the univariate analysis.

Conclusion: Prednisone dose remains the most important predictor of AVN. At doses below 60 mg, AVN occurrence is dependent on the duration of highest prednisone dose. However, for doses above 60 mg, the risk is independent of the duration. The major reduction in AVN incidence in later decades likely reflects lower use of such high prednisone doses. Particular attention should be paid to avoidance of prednisone at 60 mg doses in African-Americans, given the doubling of risk of AVN as compared to Caucasians.


ACR Abstract- AVN and SLE_MP_Table1

Predictors of Avascular Necrosis


Disclosure: R. Kallas, None; J. Li, None; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5.

To cite this abstract in AMA style:

Kallas R, Li J, Petri M. Risk Factors for Avascular Necrosis in SLE: A Multivariate Model [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-avascular-necrosis-in-sle-a-multivariate-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-avascular-necrosis-in-sle-a-multivariate-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology